Related references
Note: Only part of the references are listed.Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
Gioia Colafigli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia A Nonrandomized Clinical Trial
Ehab Atallah et al.
JAMA ONCOLOGY (2021)
Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study
Stuart Scott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Prospects for achieving treatment-free remission in chronic myeloid leukaemia
Giuseppe Saglio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia
Georg-Nikolaus Franke et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Chronic Myeloid Leukemia, Version 2.2021
Michael W. Deininger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
Camille C. B. Kockerols et al.
HEMASPHERE (2020)
Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay
Hee-Jung Chung et al.
ANNALS OF LABORATORY MEDICINE (2020)
Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA
Justin T. Brown et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
Simona Bernardi et al.
CANCER MEDICINE (2019)
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Franck Emmanuel Nicolini et al.
CLINICAL CANCER RESEARCH (2019)
Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia
Matteo Dragani et al.
LEUKEMIA & LYMPHOMA (2019)
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study
Andrea Forschner et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Optimized Digital Droplet PCR for BCR-ABL
Jacqueline Maier et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
Michele Baccarani et al.
LEUKEMIA (2019)
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients
Marius Bill et al.
ANNALS OF HEMATOLOGY (2018)
Quantification of residual BHK DNA by a novel droplet digital PCR technology
Yu Wang et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele et al.
LANCET ONCOLOGY (2018)
Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology
Jerald P. Radich et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia
Claudia Brunetti et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation
Matthew P. Mule et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Quantification of the Mutant CALR Allelic Burden by Digital PCR Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation
Olivier Mansier et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale
N. C. P. Cross et al.
LEUKEMIA (2016)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2015)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool
Jim F. Huggett et al.
CLINICAL CHEMISTRY (2015)
Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR
Lawrence J. Jennings et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Incidence of bcr-abl fusion transcripts in healthy individuals
Said I. Ismail et al.
MOLECULAR MEDICINE REPORTS (2014)
BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring
Martin H. Luu et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2013)
Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay
Hyun-Gyung Goh et al.
LEUKEMIA & LYMPHOMA (2011)
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA
Helen E. White et al.
BLOOD (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance
Dushyant Verma et al.
BLOOD (2009)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response
Richard D. Press et al.
CLINICAL CANCER RESEARCH (2007)
Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring - Summary and recommendations
Tong Zhang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
S. Branford et al.
LEUKEMIA (2006)
Share Paper
